Top 5 Drug Type | Count |
---|---|
Small molecule drug | 15 |
Therapeutic vaccine | 4 |
DNA vaccine | 1 |
Conjugated vaccine | 1 |
Prophylactic vaccine | 1 |
Top 5 Target | Count |
---|---|
DNA | 2 |
HIV integrase x RT | 2 |
thrombin(Factor IIa) | 1 |
RT(Viral reverse transcriptase) | 1 |
SARS-CoV-2 S protein | 1 |
Target |
Mechanism RT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date28 Feb 2018 |
Target |
Mechanism RT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date05 Feb 2018 |
Target |
Mechanism DNA inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 Mar 2016 |
Start Date11 Dec 2024 |
Sponsor / Collaborator |
Start Date20 Feb 2024 |
Sponsor / Collaborator |
Start Date04 Oct 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Melphalan hydrochloride ( DNA ) | Multiple Myeloma More | Approved |
Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate ( HIV integrase x RT ) | HIV Infections More | Approved |
Hydrobentizide/Olmesartan Medoxomil ( AT1R ) | Essential Hypertension More | Approved |
Permethrin ( Nav1.1 ) | Scabies More | Approved |
Levoleucovorin | Drug intoxication More | Approved |